Nucleic acid intercalating drug. The structure of 9-hydroxy-2,5,11- tetramethylpyrido[4,3-b]carbazolium (9-hydroxy-2,6- dimethylellipticinium) chloride monohydrate.
C19H19N2O.Cl. H2O, Mr = 344.6, triclinic, P1, alpha = 12.980 (1), b = 9.454 (2), c = 7.148 (1) A, alpha = 75.23 (2), beta = 99.73 (3), gamma = 91.83 (2) degree, V = 835.9 A3, Z = 2, Dm = 1.35 (2), Dx = 1.369 Mg m-3, lambda (Cu Ka) = 1.54178 A, mu = 2.11 mm-1, F(000) = 364, T 298 k, R 0.059 for 2767 observed reflections. Antitumour drug that displays one of the highest DNA affinities (4 x 10(6) M 1) among ellipticine derivatives. The structure analysis confirms the intercalation hypothesis. There is stacking of centrosymmetrically related parallel molecules along c, alternately spaced by 3.43 and 3.48 A. The crystal structure confirms the desolvation effect of the sixth nitrogen position.